$AZN plenary double, $GSK Dreamm-8, $PFE Echelon-3, $BMY Krystal-12... and no $ALXO Aspen-06.
#ASCO24 preview on ApexOnco -> oncologypipeline.com/apexonco/asco-…

$BMY overpaid. KRAS landscape changing rapidly.

$IBRX claims Anktiva 'rescued checkpoint therapy efficacy' and 'significantly prolonged OS'. I call bullshit

Remember Ronny Gal's Libtayo letter to $REGN? Now Jefferies has an idea for $BGNE

$AZN double plenary at #ASCO24

If like me you're puzzling over $IBRX claim that Anktiva showed 'positive OS' in 2/3L NSCLC (Quilt 3.055 trial has no control cohort) here are some earlier data from this study. Convincing?

$AZN Q1 pipeline changes

These ph1 data from JNJ-69086420 (JNJ-6420) coming at #ASCO24 ☢️

Dreamm-8 is confirmed as an #ASCO24 late breaker

Some seriously demob-happy quotes in this $FGEN interview

Guess what: after discontinuing the $IMCR asset and an in-house T-cell engager $RHHBY is still in Mage-A4. Third time lucky? Via ApexOnco -> oncologypipeline.com/apexonco/third…

$RHHBY stressing that termination of 20% of NMEs is a gross figure. Other projects have been added, including through M&A.

The young ADC startup Mythic Therapeutics goes back to the basics of ADC targeting with MYTX-011. I interviewed Brian Fiske on ApexOnco -> oncologypipeline.com/apexonco/node/… $ABBV $REGN $AZN